Metronidazole Special Concept Development (Uk)

Metronidazole, the active ingredient in Metronidazole Special Concept Development (Uk), is a nitroimidazole antibiotic presented as a strength/form for oral use. It treats bacterial vaginosis, trichomoniasis, amoebiasis, anaerobic bacterial infections and adjunctive Clostridioides difficile infection in adults.

GNH USA supplies Metronidazole Special Concept Development (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is a nitroimidazole antibiotic used to treat infections caused by anaerobic bacteria and certain protozoa. - Bacterial vaginosis: eradicates the anaerobic bacteria responsible for the condition, relieving discharge and odor. - Trichomoniasis: eliminates Trichomonas vaginalis, resolving genital irritation and discharge. - Amoebiasis: destroys Entamoeba histolytica trophozoites, treating intestinal and extra‑intestinal disease. - Anaerobic bacterial infections: targets intra‑abdominal, skin and soft‑tissue infections caused by obligate anaerobes. - Clostridioides difficile infection (adjunctive): reduces toxin‑producing bacteria when used alongside standard therapy.

Metronidazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing pain. - Diarrhea: loose stools that may be watery. - Abdominal pain: cramping or discomfort in the stomach area. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: convulsions requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin blistering. - Hepatotoxicity: liver enzyme elevations or failure. - Blood dyscrasias: neutropenia, thrombocytopenia, or anemia.

Before prescribing Metronidazole, clinicians should consider several safety measures. - Renal and hepatic assessment: evaluate kidney and liver function, especially in patients with impairment. - Alcohol avoidance: advise patients to abstain from alcohol to prevent disulfiram‑like reactions. - Pregnancy caution: use only if benefits outweigh potential risks. - Neurotoxicity monitoring: watch for signs of peripheral neuropathy during prolonged therapy. - Drug interaction review: check concomitant medications for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Metronidazole can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: can enhance anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity. - Cyclosporine: increased cyclosporine concentrations may occur. - Carbamazepine: reduced efficacy of carbamazepine due to enzyme induction.

Moderate Interactions (Monitor Closely): - Phenytoin: may lower metronidazole levels. - Phenobarbital: can decrease metronidazole exposure. - Rifampin: induces metabolism, reducing effectiveness. - Oral contraceptives: may reduce contraceptive reliability. - Theophylline: possible increase in theophylline serum concentrations.